Crossmark

Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit

Crossref DOI link: https://doi.org/10.1016/j.reumae.2018.11.010

Published Print: 2019-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Alvaro-Gracia, José María

Arredondo, Miguel

Daudén, Esteban

Meca-Lallana, Virginia

Morell, Alberto

Gisbert, Javier P.

Fernández-Jiménez, Guillermo

García de Vicuña, Rosario

Aspa, Francisco Javier

García de Yébenes, María Jesús

Carmona, Loreto
Funding

Funding for this research was provided by:

Abbvie

Biogen

Bristol-Myers Squibb

Janssen-Cilag

Merck Sharp & Dohme

Novartis

Pfizer

Roche

Sanofi-Aventis

UCB Pharma
License Information

Text and Data Mining valid from 2019-03-01
More Information

This article is maintained by: Elsevier

Article Title: Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2018.11.010

Content Type: article

Copyright: © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.